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pi6 mutations/deletions are not frequent events in prostate
Y Tamimi, PP Bringuier, F Smit, A van Bokhoven, FMJ Debruyne and JA Schalken
Department o f  Urology [Urological Research Laboratory, University Hospital Nijmegen, Nijmegen, The Netherlands.
Summary Cyclin-dependent kinase-4 inhibitor gene (p l61INK4) has recently been mapped to chromosome 9p21. 
Homozygous deletions of this gene have been found at high frequency in cell lines derived from different types 
of tumours. These findings suggested therefore, that pl6 4 is a tumour-suppressor gene involved in a wide 
variety of human cancers. To investigate the frequency of p l6 INK4 mutations/deletions in prostate cancer, we 
screened 20 primary prostate tumours and four established cell lines by polymerase chain reaction (PCR) and 
single-strand conformation polymorphism (SSCP) analysis for exon 1 and exon 2, In contrast to most previous 
reports, no homozygous deletions were found in prostate cancer cell lines, but one cell line (DU 145) has 
revealed a mutation at codon 76. Only two SSCP shifts were detected in primary tumours: one of them 
corresponds to a mutation at codon 55 and the other one probably corresponds to a polymorphism. These data 
suggest that mutation of the p l6INK4 gene is not a frequent genetic alteration implicated in prostate cancer 
development.
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Cyclin-dependent kinases (CDKs) are key enzymes in driving 
cells through the cell cycle into mitosis. Their activity is tightly 
controlled by phosphorylation and dephosphorylation of the 
CDK itself and association with regulatory subunits. Binding 
of a specific cyclin is a prerequisite for kinase activity. On the 
other hand, CDK inhibitory subunits have been recently 
described. p21 and p27 share a region of homology, and form 
with CDK and cyclins ternary complexes that can inhibit a 
variety of CDKs (Polyak el al., 1994; Nasmyth and Hunt, 
1993). p l6 lNM was the first identified member (Serrano et al
1993) of a growing family of proteins that specifically inhibit 
CDK4 and CDK6 (Kamb et a l ,  1994; Nobori et a l ,  1994; 
Hannon and Beach, 1994). These two CDKs act together with 
cyclin D to control Rb phosphorylation and passage through 
the starting point of the cell cycle. This is a crucial step in 
controlling cell growth and perturbation of this pathway is 
thought to be implicated in carcinogenesis (Kamb et al., 1994).
samples o f various Gleason grades (G g2-G g5) were obtained 
by transurethral resection of the prostate, and then frozen in 
liquid nitrogen. Areas containing at least 70% of tumour cells 
as judged by step sectioning, were subjected to DNA  
extraction (Miller et al., 1988).
I N K 4
Polymerase chain reaction ( PCR)
We amplified exon 1 and exon 2 for the analysis of p 16 
gene alterations in prostate cancer. Primer sequences used for 
amplification were: 5'-GAAGAAGAGGAGGGGCTG-3' 
and 5'-GCGCTACCTGATTCCAATTC-3' for exon 1. Two 
overlapping primer sets were taken to cover the entire 500 bp 
long exon 2: 5'-GCAGCACCACCAGCGTGTCC-3' and 5'- 
GGAAATTGGA A ACTGGAAGC -3'5' - TCTGTTCTCTCT- 
GGCAGGTC - 3' and 5' - TCTGAGCTTTGGAAGCTCT -3'.
Purified D N A  (50 ng) was amplified in a total volume of
Moreover, the gene encoding p 16 protein, (p i6WMjCDKNj  50 /¿I using 50 pmol of sense and antisense primers, 200 /;M
MTS1)  has been recently located in the chromosomal region 
9p21, a critical area of allelic loss in a wide spectrum of human 
tumours (Serrano et a l 1993; Kamb et al., 1994; Nobori et al., 
1994). Interestingly, a high frequency of homozygous deletions 
in the p l6INM gene in cell lines derived from a variety of human 
tumours including bladder and kidney have been reported 
(Kamb et a/., 1994). The mutation rate found in cell lines could 
even rival that of the p53 tumour-suppressor gene. However, in 
primary tumours the rate of p l6 INK4 mutations seems to be 
rather low and varies in a tumour 
(Mori et al., 1994; Cairns et al., 1994; Spruek et al., 1994).
Here we investigated the alterations of p l6 ,NM in cell lines 
and primary tumours of the prostate using the polymerase
manner
chain reaction and single-strand conformation
polymorphism (SSCP) analysis.
M aterials and methods
Patient samples, cell lines and DNA isolation
Four established prostatic cell 
LNCaP) were grown in RPMI 
calf serum until they reach 
according to Miller et a l
(PC3, DU 145, TSUprl,
ium containing 10% of 
. DNA was extracted
Twenty prostate cancer
of each dNTP, 1 x amplification buffer (17 mM ammonium 
sulphate, 67 mM Tris pH 8.8, 2 mM magnesium 
10 mM /?-mercaptoethanol, 6.7 /¿M EDTA), 2.5 mM magne­
sium chloride for exon 1, 1.5 mM magnesium chloride for 
exon 2 and 0.5 pi (2.5 unit) of Taq polymerase (Perkin 
Elmer). Dimethyl sulphoxide (5%) was added for each DNA  
amplification reaction. For SSCP analysis 0.3 /¿I [a-u,P]dATP
to the(370 MBq ml - 1 110 TBq mmol ') was
reaction. Forty cycles of 50 s at 94"C, 40s at 61“C, 40 s at 
72"C were carried out in a Perkin-Elmer thermal cycler. The 
PCR products were subsequently analysed by electrophoresis 
on 2% agarose gels.
SSCP analysis
The reaction product (3 pi) was then mixed with 10 /¿I of
wereloading buffer containing 96% formamide. 
denatured at 94°C for 3 min, chilled on ice for at least 5 min 
and 2 pi was loaded onto a 6% non-denaturing polyacryla-
without 10% glycerol. were
5 W (with glycerol) and 3 W (without
glycerol) at room arature, 0.5 x Tris-
borate-ED TA  buffer. Gels were dried and exposed to (RPN 
8 3 5 x 4 3  cm) Amersham film at — 80"C for 3 days.
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Sequence analysis
PCR products displaying a shift on SSCP analysis were 
sequenced both directly, as described before (Jacoby et al.,
1994) and after being cloned into TA cloning vector (pCR II; 
Invitrogen).
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Results and discussion primary and recurrent cancer were analysed by
INK4We have studied the mutation frequency in the MTS 1/p i6 
gene, in prostate cancer. Exon 1 and exon 2 represent the 
major part o f  the coding sequence (98% o f the p i 6 protein), 
whereas exon 3 makes up only 11 coding nucleotides (2% of  
the total coding sequence). Amplification of tumour genomic 
DNA using primers for exon 1 and exon 2 o f  the p l6 lNK4 
gene resulted in bands of the predicted size 350, 240 and 
340 bp respectively when separated on 2% agarose gel. A 
PCR product of the expected size was obtained in each of the 
four prostatic cell lines, indicating that none o f  them has a 
homozygous deletion of the pi 6 gene.
We subsequently investigated the presence of point
comparative genomic hybridisation (CGH) (Visakorpi et al ., 
1995), a new technique enabling the survey o f  the entire 
genome for gains and losses of D N A  sequences (du Manoir 
ct a l 1993). Losses most often involved 8p (32%), 13q 
(32%), 6q (22%), 16q (19%), 18q (19%) and 9p (16%) 
(Visakorpi et al., 1995). Hence, the frequency of 9p losses 
seems higher than the frequency of p 16 mutations we found 
in this study, suggesting that another gene is the major 
target on 9p.
At present, the role played by the p l6 INK4 gene in human 
cancer remains controversial. For instance, in a recent study 
using primary tumours from a variety of organ types, which
were previously shown to have of
mutations in exon 1 and exon 2 fragments o f  the p l6 INK4 involving 9p21 p22, p 16 mutations were found in less than
gene by SSCP analysis, a technique that is sensitive enough to 
detect more than 80% of mutations (Sheffield et al., 1993). 
The screening of almost the entire coding sequence (98%) o f  
p l6INK4 revealed band migration shifts, for exon 2, in one cell 
line (DU 145) and two primary tumours (see example in 
Figure 1, sample 21).
The corresponding PCR products were sequenced. This 
revealed a missense mutation in D U  145 at codon 76 
(GAC-*TAC) resulting in a change from aspartic acid to 
tyrosine (see example in Figure 2). The shift found in one o f  
the primary tumours (case 166) was a mutation at codon 55 
(CTG-+CCG) leading to a change from leucine to proline. 
It remains to be determined whether the substitution of the 
Asp with Tyr and Leu with Pro at codons 76 and 55 
respectively plays a part in prostate cancer development. The 
shift in the other primary tumour (case 154) corresponded to 
a GCG-+ACG transition at codon 140 leading to a change 
from alanine to threonine. This change was previously 
reported and is thought to represent a polymorphism as it 
has also been found in white blood cells (Spruck et al.,
1994).
Genetic aberrations involved in prostate cancer have 
been taken into consideration previously and partly studied. 
Likewise, loss o f  heterozygosity (LOH) studies, identifying 
chromosomal regions harbouring potential tumour-suppres­
sor genes, have mainly revealed 8p, lOq, 13q, 16q and 18q 
(Bergerheim et al., 1991; Bova et a t 1993; Phillips et al.,
1994). However, most LOH are limited to the
analysis of a few chromosomes leaving the major part of
3% (Cairns et al., 1994). Mutations within the non-coding 
region, rearrangement and down-regulation of p 16 could play 
a role in the inactivation of this gene in some cases (Cheng et
al., 1994). Furthermore, mutations within promoter
region may alter the normal expression o f  the p 16 gene, 
although this type of mutation has not been reported to be a 
predominant mechanism of gene inactivation in human 
cancer (Cairns et al., 1994).
Using SSC P-PC R  analyses on four established prostatic 
cell lines and 20 primary tumours, we were not able to find 
more than two mutations: one in the D U  145 cell line, and 
one in primary tumours. These results indicate that mutation 
of the p l6 INK4 gene is not a frequent genetic change in the 
formation of primary prostate cancer. Moreover, in contrast 
to several reports in which homozygous deletion in cultured 
cell lines can reach 85% (Kamb et al., 1994), homozygous 
deletions in established lines o f prostate cancer were not 
found in the four analysed cases. Parallel to our 
observations on primary prostatic tumours, analysis o f  
tumours from several organs such as astrocytomas (Ueki 
et al., 1994), breast (Xu et al., 1994), bladder (Cairnes et al., 
1994); Spruck et al., 1994), lung, brain and kidney tumours 
(Cairns et a l 1994) revealed p l6 INK4 mutations in only a 
small fraction of primary tumours. Alternatively, 
frequencies have been found in some tumour types: 16% in 
head and neck squamous cell carcinoma and up to 51% in 
oesophageal squamous cell carcinomas have been detected 
recently (Mori et a l ,  1994). Therefore, the p l6 ,NK4 gene has 
certainly a key role in certain cases, but not in all tumour
the genome unexamined. Recently, changes in
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INK4Figure 1 A representative example o f  SSCP analysis o f  p i6 
gene (exon 2) in primary tumour and established cell lines of the 
prostate. A migration shift displayed by one primary tumour 
(sample 21).
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Figure 2 A representation of D N A  sequencing of the SSCP shift 
observed in D U  145 prostate cancer cell line. A base substitution 
from cytidine to adenosine in the non-coding .strand is indicated 
by an arrow. This base substitution leads to a change from 
guanine to thymine at codon 76 and results in an amino acid 
change from aspartic acid to tyrosine.
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